Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49.

Article  PubMed  Google Scholar 

Waks AG, Winer EP. Breast Cancer Treatment: a review. JAMA. 2019;321(3):288–300.

Article  CAS  PubMed  Google Scholar 

Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.

Article  CAS  PubMed  Google Scholar 

Richman J, Dowsett M. Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer. Nat Rev Clin Oncol. 2019;16(5):296–311.

Article  CAS  PubMed  Google Scholar 

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-Year risks of breast-Cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–46.

Article  PubMed  PubMed Central  Google Scholar 

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, et al. Adjuvant palbociclib for early breast Cancer: the PALLAS Trial results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2022;40(3):282–93.

Article  CAS  PubMed  Google Scholar 

Chavez-MacGregor M, Miao J, Pusztai L, Goetz MP, Rastogi P, Ganz PA, et al. Phase III randomized, placebo-controlled trial of endocrine therapy ± 1 year of Everolimus in patients with High-Risk, hormone Receptor-Positive, early-stage breast Cancer. J Clin Oncol. 2024;42(25):3012–21.

Article  CAS  PubMed  Google Scholar 

Zahari S, Syafruddin SE, Mohtar MA. Impact of the Cancer Cell Secretome in driving breast Cancer progression. Cancers (Basel). 2023;15(9).

Carlsson A, Wingren C, Kristensson M, Rose C, Fernö M, Olsson H, et al. Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases. Proc Natl Acad Sci U S A. 2011;108(34):14252–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Madden EC, Gorman AM, Logue SE, Samali A. Tumour Cell Secretome in Chemoresistance and Tumour recurrence. Trends Cancer. 2020;6(6):489–505.

Article  CAS  PubMed  Google Scholar 

Majidzadeh AK, Gharechahi J. Plasma proteomics analysis of tamoxifen resistance in breast cancer. Med Oncol. 2013;30(4):753.

Article  Google Scholar 

Fu X, Pereira R, Liu CC, De Angelis C, Shea MJ, Nanda S, et al. High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer. Cell Rep. 2023;42(8):112821.

Article  CAS  PubMed  Google Scholar 

Kim KE, Park I, Kim J, Kang MG, Choi WG, Shin H, et al. Dynamic tracking and identification of tissue-specific secretory proteins in the circulation of live mice. Nat Commun. 2021;12(1):5204.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei W, Riley NM, Yang AC, Kim JT, Terrell SM, Li VL, et al. Cell type-selective secretome profiling in vivo. Nat Chem Biol. 2021;17(3):326–34.

Article  CAS  PubMed  Google Scholar 

Yang R, Meyer AS, Droujinine IA, Udeshi ND, Hu Y, Guo J, et al. A genetic model for in vivo proximity labelling of the mammalian secretome. Open Biol. 2022;12(8):220149.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Swietlik JJ, Bärthel S, Falcomatà C, Fink D, Sinha A, Cheng J, et al. Cell-selective proteomics segregates pancreatic cancer subtypes by extracellular proteins in tumors and circulation. Nat Commun. 2023;14(1):2642.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim SS, Lee MH, Lee MO. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells. Breast Cancer Res Treat. 2020;180(1):45–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ka NL, Lim GY, Hwang S, Kim SS, Lee MO. IFI16 inhibits DNA repair that potentiates type-I interferon-induced antitumor effects in triple negative breast cancer. Cell Rep. 2021;37(12):110138.

Article  CAS  PubMed  Google Scholar 

DeCicco-Skinner KL, Henry GH, Cataisson C, Tabib T, Gwilliam JC, Watson NJ et al. Endothelial cell tube formation assay for the in vitro study of angiogenesis. J Vis Exp. 2014(91):e51312.

Choi YS, Kim MJ, Choi EA, Kim S, Lee EJ, Park MJ, et al. Antibody-mediated blockade for galectin-3 binding protein in tumor secretome abrogates PDAC metastasis. Proc Natl Acad Sci U S A. 2022;119(30):e2119048119.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hwang S, Park S, Kim JH, Bang SB, Kim HJ, Ka NL, et al. Targeting HMG-CoA synthase 2 suppresses tamoxifen-resistant breast cancer growth by augmenting mitochondrial oxidative stress-mediated cell death. Life Sci. 2023;328:121827.

Article  CAS  PubMed  Google Scholar 

Capone E, Iacobelli S, Sala G. Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target. J Transl Med. 2021;19(1):405.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gearing LJ, Cumming HE, Chapman R, Finkel AM, Woodhouse IB, Luu K, et al. CiiiDER: a tool for predicting and analysing transcription factor binding sites. PLoS ONE. 2019;14(9):e0215495.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rauluseviciute I, Riudavets-Puig R, Blanc-Mathieu R, Castro-Mondragon JA, Ferenc K, Kumar V, et al. JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2024;52(D1):D174–82.

Article  CAS  PubMed  Google Scholar 

Lin TW, Chang HT, Chen CH, Chen CH, Lin SW, Hsu TL, et al. Galectin-3 binding protein and Galectin-1 Interaction in breast Cancer cell aggregation and metastasis. J Am Chem Soc. 2015;137(30):9685–93.

Article  CAS  PubMed  Google Scholar 

Sasaki T, Brakebusch C, Engel J, Timpl R. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin. Embo j. 1998;17(6):1606–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Piccolo E, Tinari N, Semeraro D, Traini S, Fichera I, Cumashi A, et al. LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. J Mol Med (Berl). 2013;91(1):83–94.

Article  CAS  PubMed  Google Scholar 

Traini S, Piccolo E, Tinari N, Rossi C, La Sorda R, Spinella F, et al. Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. Mol Cancer Ther. 2014;13(4):916–25.

Article  CAS  PubMed  Google Scholar 

Aouad P, Zhang Y, De Martino F, Stibolt C, Ali S, Ambrosini G, et al. Epithelial-mesenchymal plasticity determines estrogen receptor positive breast cancer dormancy and epithelial reconversion drives recurrence. Nat Commun. 2022;13(1):4975.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Augustine TN, Buthelezi S, Pather K, Xulu KR, Stoychev S. Secretomics reveals hormone-therapy of breast cancer may induce survival by facilitating hypercoagulation and immunom